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We examined plasma concentrations of phyto-oestrogens in relation to risk for subsequent prostate cancer in a case–control study
nested in the European Prospective Investigation into Cancer and Nutrition. Concentrations of isoflavones genistein, daidzein and
equol, and that of lignans enterolactone and enterodiol, were measured in plasma samples for 950 prostate cancer cases and 1042
matched control participants. Relative risks (RRs) for prostate cancer in relation to plasma concentrations of these phyto-oestrogens
were estimated by conditional logistic regression. Higher plasma concentrations of genistein were associated with lower risk of
prostate cancer: RR among men in the highest vs the lowest fifth, 0.71 (95% confidence interval (CI) 0.53–0.96, P trend¼0.03). After
adjustment for potential confounders this RR was 0.74 (95% CI 0.54–1.00, P trend¼0.05). No statistically significant associations
were observed for circulating concentrations of daidzein, equol, enterolactone or enterodiol in relation to overall risk for prostate
cancer. There was no evidence of heterogeneity in these results by age at blood collection or country of recruitment, nor by cancer
stage or grade. These results suggest that higher concentrations of circulating genistein may reduce the risk of prostate cancer but do
not support an association with plasma lignans.
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International comparisons, small randomised trials and experi-
mental data from animal models and cell lines suggest a possible
protective association between dietary phyto-oestrogens, including
isoflavones and lignans, and the development of prostate cancer
(Goetzel et al, 2007; Perabo et al, 2008). Results from prospective
epidemiological studies of dietary phyto-oestrogen intake and
prostate cancer risk generally support this hypothesis (Severson
et al, 1989; Jacobsen et al, 1998; Allen et al, 2004; Nomura et al,
2004; Low et al, 2006; Kurahashi et al, 2007), previous studies of
circulating concentrations of lignans have been inconclusive
(Stattin et al, 2002, 2004; Kilkkinen et al, 2003; Ward et al,
2008), and there have been no large-scale prospective investiga-
tions of circulating concentrations of isoflavones in relation to
prostate cancer risk.
Here, we report the findings from the first large prospective
study of plasma concentrations of isoflavones in relation to risk for
prostate cancer, presenting data on prediagnostic plasma con-
centrations of genistein, daidzein and equol among 950 men with
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participating in the European Prospective Investigation into
Cancer and Nutrition (EPIC). We also examine associations with
plasma concentrations of the lignans enterolactone and enterodiol,
and evaluate the associations of isoflavones and lignans with risk
subdivided by the stage of disease and other factors.
MATERIALS AND METHODS
Participants and data
Between 1992 and 2000, B500000 individuals (150000 men) were
recruited into EPIC from 23 centres in 10 European countries. The
methods of recruitment and study design have been described in
detail elsewhere (Riboli et al, 2002). The participants completed an
extensive questionnaire on dietary and non-dietary factors at
recruitment, and about 400000 individuals (of whom 137000 were
men) also provided a blood sample. All participants gave written
consent for the research, and approval for the study was obtained
from the Internal Review Board of the International Agency for
Research on Cancer (Lyon, France) and from the local ethics
committees in the participating countries.
This study includes prostate cancer cases occurring after blood
collection and individually matched male control participants
from the eight participating countries, which recruited men:
Denmark, Germany, Greece, Italy, the Netherlands, Spain, Sweden
and the United Kingdom.
Follow-up for diagnosis of prostate cancer is provided through
record linkage with population-based cancer registries in six of the
participating countries: Denmark, Italy, the Netherlands, Spain,
Sweden and the United Kingdom. In Germany and Greece, follow-
up is active and is achieved through checks of insurance records
and cancer and pathology registries, as well as through
self-reported questionnaires; self-reported incident cancers are
verified through medical records. Data on vital status in most EPIC
study centres were collected from mortality registries at the
regional or national level, in combination with data collected by
active follow-up (Greece). The 10th Revision of the International
Statistical Classification of Diseases, Injuries and Causes of Death
was used, and cancer of the prostate was defined as code C61. For
each EPIC centre closure dates of the study period were defined as
the latest dates of complete follow-up for both cancer incidence
and vital status (dates varied between centres, from June 1999 to
January 2003).
Case patients were men who developed prostate cancer after the
date of blood collection and before the end of the study period,
defined for each study centre by the latest date of follow-up. The
cases with no available blood sample and those participants who
had missing information on the date of the blood donation, or who
had a history of another cancer (except non-melanoma skin
cancer) at the time of the blood collection, were excluded. After
these exclusions, laboratory measures for the current analysis were
available for 950 cases: 288 cases in Denmark, 201 in Germany, 9 in
Greece, 62 in Italy, 25 in the Netherlands, 93 in Spain, 94 in Sweden
and 178 in the United Kingdom.
Data on the stage and grade of disease at diagnosis were
collected from each centre, where possible. A total of 675 cases
(71.1%) had information on tumour stage; of these 475 (50.0%)
were classified as localised (tumour (T)-node (N)-metastasis (M)
categories T0 or T1 or T2 and N0 or NX and M0, or stage coded in
recruitment centre as localised), and 200 (21.1%) were classified as
advanced (T3 or T4, N1þ, M1, or some combination of these, or
stage coded in recruitment centre as metastatic). Information on
histological grade was available for 720 cases (75.8%); of these, 441
(46.4%) were classified as low-grade (Gleason sum o7o r
equivalent, i.e. coded as moderately or as well differentiated) and
279 (29.4%) were classified as high-grade (Gleason sum X7o r
equivalent, i.e. coded as poorly differentiated or as undifferen-
tiated).
Each case patient was matched to one control participant, with
the exception of cases from Umea ˚, an EPIC-associated cohort in
which case patients were matched to two control participants,
selected at random among appropriate risk sets consisting of all
male cohort members alive and free of cancer (except non-
melanoma skin cancer) at the time of diagnosis of the index case.
An incidence density sampling protocol for control selection was
used, such that controls could include participants who became a
case later in time, whereas each control participant could also be
sampled more than once. Matching criteria included: recruitment
centre, age at enrolment (±6 months), time of day of blood
collection (±1h), follow-up time (as close as possible), time
between blood draw and last consumption of food or drinks (o3,
3–6, 46h).
Laboratory assays
Plasma samples were analysed for three isoflavones (genistein,
daidzein and equol) and two lignans (enterolactone and enter-
odiol) using ultra performance liquid chromatography–tandem
mass spectrometry in the HFL laboratory, Fordham, UK using an
adaptation of an earlier published method (Grace et al, 2007). The
laboratory personnel who conducted the assays were blinded to the
case or control status of the participants. Plasma samples from
each case–control set were assayed within the same batch and
analysed on the same day. Three quality control plasma samples
were inserted into each assay batch and analysed in duplicate.
The quality control samples contained concentrations of
genistein, daidzein, equol, enterolactone and enterodiol, which
reflected low, medium and high ranges of the calibration chart
(0.1–500ngml
–1, e.g. equivalent to 0.37–1850nmoll
–1 of genis-
tein). The average intra-assay co-efficient of variation (CV) ranged
from 3.1 (enterolactone) to 5.9% (equol). The average inter-assay
CVs ranged from 4.1 (enterodiol) to 6.2% (equol).
The lower limit of quantification, equivalent to the lowest point in
the calibration curve, was 0.1ngml
–1for each analyte (equivalent to
0.37nmoll
–1of genistein, 0.39nmoll
–1of daidzein, 0.41nmoll
–1of
equol, 0.34nmoll
–1 of enterolactone and 0.33nmoll
–1 of enter-
odiol); the percentage of samples in which levels were not detectable
was 16% for genistein, 13% for daidzein, 43% for equol, 2% for
enterolactone and 16% for enterodiol. For individuals with levels
below this limit, phyto-oestrogen concentrations were imputed at
0.05ngml
–1 (equivalent to B0.2nmoll
–1).
Statistical analysis
Statistical analyses were carried out with the Stata 9 statistical
software package (StataCorp, 2005). All tests of statistical
significance were two-sided, and P-values below 0.05 were
considered significant.
Differences in baseline characteristics of cases and controls were
compared using conditional logistic regression models for
categorical variables or a weighted paired t-test for continuous
variables, comparing the value for the case with the value in the
matched control participant, or the mean of the values in controls
when there were two matched controls in a set (Rosner, 1982).
Spearman’s rank correlation coefficients were calculated to
assess the correlations between plasma levels of phyto-oestrogens
among control participants.
Conditional logistic regression models were applied to calculate
the relative risks (RRs) (odds ratios) for prostate cancer in relation
to fifths of genistein, daidzein, enterolactone and enterodiol
concentrations, using cut points defined by the quintiles among
control participants for all centres combined and using the lowest
category as reference. For equol, given the high proportion of
values below the lower limit of quantification and an interest in the
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was as follows: not detected (non-producers), and those with
detectable levels of equol (producers) divided into fourths using
cut points defined by the quartiles of equol concentration among
control participants for all centres combined. Likelihood ratio tests
were used to assess heterogeneity, and tests for linear trend were
obtained using a continuous variable with values equal to the
median concentration within each quintile of plasma phyto-
oestrogen concentration.
To examine the effects of potential confounders (other than
the matching criteria, controlled for by design), the analyses
were repeated including additional variables in the logistic
regression models. These variables were smoking (never,
past and present), body mass index (BMI, kgm
–2; in fourths),
physical activity (inactive, moderately inactive and active)
(Friedenreich et al, 2007) (we combined the ‘moderately active’
and ‘active’ categories), alcohol intake (o8, 8–15, 16–39, X40g
per day), marital status (married/cohabiting or not married/
cohabiting) and education level (primary or none, secondary and
degree level). For each of these variables a small proportion of
values was unknown; these values were included in the analyses as
a separate category.
Likelihood ratio w
2-tests were used to examine the heterogeneity
of the associations of phyto-oestrogen concentrations with risk of
prostate cancer categorised according to prostate tumour stage
(localised or advanced), histologic grade (low grade or high grade)
and time to diagnosis (o4 years after blood collection, X4 years
after blood collection). Likelihood ratio w
2-tests were also used to
examine the heterogeneity of the associations of phyto-oestrogen
concentrations with prostate cancer risk for participants cate-
gorised by age at blood collection (o60 or X60 years) and by
country of recruitment (eight countries).
RESULTS
Nine hundred and fifty men diagnosed with prostate cancer from
recruitment until the end of follow-up and 1042 matched
participants without prostate cancer were included in the analyses.
Their median age at blood collection was 60 years (range¼43–76
years).
When the characteristics of case patients and control partici-
pants were compared, the groups did not differ appreciably in
most respects, but there were some small differences (Table 1).
Compared with control participants, case patients had a slightly
lower mean weight (80.1 and 81.1kg, respectively) and lower mean
BMI (26.6 and 26.8kgm
–2, respectively), were less likely to be
current smokers (24.3 and 28.7%, respectively), and were less
likely to be physically active (43.7 and 49.3%, respectively).
Prostate cancer diagnosis followed blood collection by a median
of 4.2 years (range o1–15.1 years) and the median age at
diagnosis was 65 years (range 47–82 years).
Correlations between the plasma concentrations of the indivi-
dual phyto-oestrogens among control participants were strongest
between genistein and daidzein (r¼0.71, Po0.001) and between
the lignans, enterolactone and enterodiol (r¼0.38, Po0.001).
Genistein and daidzein were weakly correlated with the lignans
(r¼0.08–0.19). Plasma concentrations of equol were not sig-
nificantly correlated with the concentrations of any of the other
analytes.
Table 2 shows median plasma concentrations of genistein,
daidzein, equol, enterolactone and enterodiol, with 5th to 95th
percentiles, in study controls, overall and in the eight countries
participating in the study. There was substantial variation in the
median concentrations between the countries, with participants in
the United Kingdom and the Netherlands generally having the
highest levels of isoflavones and participants in Denmark having
the highest levels of lignans.
Table 3 shows the median plasma concentrations of genistein,
daidzein, equol, enterolactone and enterodiol in case patients and
control participants. The only weighted paired t-test of the
differences between cases and controls that was statistically
significant was for genistein (median concentrations 1.8 and
2.1ngml
–1, respectively, P¼0.007).
Table 4 shows the RRs for prostate cancer by plasma phyto-
oestrogen concentration. There was a statistically significant
inverse association between genistein and risk for prostate cancer;
Table 1 Characteristics of prostate cancer patients and control
participants
Characteristic
Cases
(n¼950)
Controls
(n¼1042)
Mean age at blood collection (years) 60.4 (5.8) 60.1 (5.8)
Weight (kg)
a 80.1 (11.2) 81.1 (11.9)
Height (cm)
a 173.6 (6.9) 173.8 (6.8)
BMI (kgm
–2)
a 26.6 (3.4) 26.8 (3.6)
Smoking, % (n)
a
Never 32.4 (301) 31.1 (309)
Former 43.3 (402) 40.2 (400)
Current 24.3 (226) 28.7 (285)
Alcohol consumption, % (n)
a
o8g per day 34.8 (322) 37.2 (371)
8–15g per day 19.9 (184) 20.7 (207)
16–39g per day 26.2 (243) 23.2 (231)
X40g per day 19.1 (177) 18.9 (189)
Physical activity, % (n)
a
Inactive 21.5 (192) 19.0 (179)
Moderately inactive 34.9 (312) 31.7 (299)
Active 43.7 (391) 49.3 (464)
Marital status, % (n)
a
Married or cohabiting 89.2 (494) 88.2 (559)
Not married or cohabiting 10.8 (60) 11.8 (75)
Educational attainment, % (n)
a
Primary or equivalent 37.9 (347) 40.3 (400)
Secondary 35.8 (328) 37.3 (370)
Degree 26.3 (241) 22.5 (223)
Cases only
Time to diagnosis (years), % (n)
b —
o2 18.3 (174)
2–o4 28.1 (267)
4–o6 30.1 (286)
6–o8 16.0 (152)
X8 7.5 (71)
Year of diagnosis, median (range) 2000 (1994–2005) —
Age at diagnosis 64.9 (5.7) —
Stage, % (n)
Localised 50.0 (475) —
Advanced 21.1 (200) —
Unknown 29.0 (275) —
Grade, % (n)
Low grade
c 46.4 (441) —
High grade
d 29.4 (279) —
Unknown 24.1 (230) —
BMI¼body mass index. Values are means (s.d.) except where indicated.
aUnknown
for some participants; the calculations of percentages exclude missing values.
bTime
between blood collection and diagnosis among case patients.
cGleason score o7o r
coded as well or moderately differentiated.
dGleason score X7 or coded as poorly
differentiated or undifferentiated.
Plasma phyto-oestrogens and prostate cancer risk in EPIC
RC Travis et al
1819
British Journal of Cancer (2009) 100(11), 1817–1823 & 2009 Cancer Research UK
E
p
i
d
e
m
i
o
l
o
g
ycompared with the men in the lowest fifth of genistein concentra-
tion, men in the highest fifth had a RR of disease of 0.71 (95%
confidence interval (CI) 0.53, 0.96; P linear trend¼0.032). When
the analysis was repeated, additionally adjusting for smoking, BMI,
physical activity, alcohol intake, marital status and education level,
this association was borderline statistically significant (RR: 0.74,
95% CI 0.54, 1.00; P linear trend¼0.051). We observed no
statistically significant association between risk for prostate cancer
and the concentrations of daidzein, equol, enterolactone or
enterodiol, with or without adjustment for potential confounders.
There was no statistical evidence of heterogeneity in the trends in
risk for prostate cancer according to the age of the men at blood
collection, nor by country of recruitment. Neither there was
statistical evidence of heterogeneity in the associations of phyto-
oestrogen concentrations with risk of prostate cancer categorised
according to prostate tumour stage, histological grade or time to
diagnosis (data not shown).
DISCUSSION
In this first large prospective study, higher plasma concentrations
of genistein were associated with a lower risk of prostate cancer.
Risk for prostate cancer did not vary significantly by plasma
concentration of daidzein or equol or by plasma concentrations of
the lignans, enterolactone and enterodiol.
The design of this study offers several methodological advan-
tages. The direct measurement of phyto-oestrogen concentrations
in the circulation makes it possible to capture phyto-oestrogen
exposure from all sources, including those that may be inade-
quately represented in food composition databases. For example,
although the most abundant sources of isoflavones in the diet are
soy foods, such as tofu and soymilk, the intake of which is low but
variable across the European countries in EPIC (Keinan-Boker
et al, 2002), soy additives are now also found in an increasing
range of processed foods (Liggins et al, 2002). Isoflavones are also
present in certain other vegetables, fruits and nuts (Liggins et al,
2000a,b), although in much lower concentrations than in soy
foods. We were also able to assess exposure to specific phyto-
oestrogens, which is particularly important as individual phyto-
oestrogens have been found to differ in their biological activity,
(Magee and Rowland, 2004) and the phyto-oestrogens absorbed
through the intestine are dependent not only on dietary intake of
phyto-oestrogens and their precursors, but also on the activity of
intestinal bacteria that metabolise phyto-oestrogens (Rowland
et al, 2003). Further strengths of this study include the large
sample size and the varied dietary habits of the study population,
linked with variation in plasma phyto-oestrogens levels across the
different countries participating in the study (Peeters et al, 2007).
Our findings for plasma genistein are consistent with the findings
from one small prospective study on circulating concentrations of
isoflavones and prostate cancer, which found a non-significant
dose-dependent reduction in risk in relation to concentrations of
genistein among 40 men with prostate cancer and 101 without
prostate cancer from the Japanese Collaborative Cohort Study
(Ozasa et al, 2004). The only other published studies we are aware of
are the EPIC-Norfolk analyses of a total of 193 men with prostate
cancer, 141 of whom are included in this study (Low et al, 2006;
Ward et al, 2008), in which no associations were found between
serum levels of phyto-oestrogens and risk of prostate cancer.
Findings from the Japanese study (Ozasa et al, 2004) also
suggested a modest and non-significant reduction in risk in
relation to daidzein, which is consistent with the non-significant
reduction in this study. This possible relationship may be a
consequence of the association between genistein and risk, given
the close correlation between circulating concentrations of these
isoflavones. The findings from this study for equol, a metabolite of
daidzein formed by microflora in the intestine, are in accordance
with data from the Japanese study, which suggested no significant
association (Ozasa et al, 2004). However, we have limited power in
this study to assess the relationship among our study participants,
as a high proportion of participants had negligible circulating
Table 2 Median (5–95 percentile) concentrations of phyto-oestrogens
a among controls by country
Phyto-oestrogen
(ngml
–1)
Denmark
n¼288
Germany
n¼201 Greece n¼9 Italy n¼62
The
Netherlands
n¼25 Spain n¼93 Sweden n¼186
The United
Kingdom
n¼178 Total n¼1042
Genistein 2.0 (0.05–23.8) 2.2 (0.05–23.5) 0.05 (0.05–17.2) 1.3 (0.05–10.3) 4.6 (0.2–40.1) 1.2 (0.05–7.4) 1.1 (0.05–14.9) 5.4 (0.2–41.5) 2.1 (0.05–24.5)
Daidzein 1.4 (0.05–12.8) 1.0 (0.05–13.9) 0.3 (0.05–0.9) 0.3 (0.05–16.2) 2.7 (0.5–25.0) 0.5 (0.05–2.4) 0.6 (0.05–7.8) 3.6 (0.2–20.2) 1.1 (0.05–13.9)
Equol 0.1 (0.05–0.9) 0.05 (0.05–0.7) 0.05 (0.05–0.6) 0.05 (0.05–1.7) 0.05 (0.05–0.5) 0.1 (0.05–0.7) 0.5 (0.05–1.4) 0.15 (0.05–0.8) 0.1 (0.05–1.0)
Enterolactone 5.5 (0.6–28.1) 3.6 (0.3–15.1) 2.0 (0.9–40.1) 2.7 (0.1–17.0) 3.8 (0.05–23.0) 2.2 (0.2–8.2) 3.6 (0.7–16.2) 3.7 (0.5–21.0) 3.7 (0.4–20.4)
Enterodiol 0.4 (0.05–6.6) 0.3 (0.05–3.5) 0.1 (0.05–0.8) 0.4 (0.05–2.9) 0.1 (0.05–3.7) 0.1 (0.05–1.3) 0.2 (0.05–1.6) 0.3 (0.05–2.1) 0.3 (0.05–2.9)
aFor participants with undetected phyto-oestrogens levels, data were imputed at 0.05ngml
–1, half the lower limit of detection.
Table 3 Median plasma phyto-oestrogen concentrations (5–95 percentile) among prostate cancer case patients and control participants
a
Median concentration (5–95 percentile), ngml
–1
Phyto-oestrogen
Number of
cases/controls Not detected
b, n (%) Case patients Control participants P for difference
c
Genistein 950/1042 317 (15.9) 1.8 (0.05–22.3) 2.1 (0.05–24.5) 0.007
Daidzein 950/1042 250 (12.6) 1.1 (0.05–11.6) 1.1 (0.05–13.9) 0.114
Equol 950/1042 855 (42.9) 0.2 (0.05–1.0) 0.1 (0.05–1.0) 0.119
Enterolactone 950/1042 34 (1.7) 3.8 (0.2–19.5) 3.7 (0.4–20.4) 0.473
Enterodiol 950/1042 327 (16.4) 0.3 (0.05–2.9) 0.3 (0.05–2.9) 0.603
aCase patients and control participants were matched on recruitment centre, age at enrolment (±6 months), time of day of blood collection (±1h), follow-up time (as close as
possible), time between blood draw and last consumption of food or drinks (o3, 3–6, 46h).
bNot detected; data for these participants were imputed at 0.05ngml
–1, half the
lower limit of detection.
cTwo-sided P-values; weighted paired t-test, using the mean value in controls for each case–control set with more than one control.
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is dependent on both the consumption of daidzein and on being an
‘equol-producer’; B30–50% of individuals do not excrete equol
when challenged daily with soy foods (Setchell et al, 2002).
The findings from this study do not support the hypothesis that
circulating lignans play a major role in the pathogenesis of prostate
cancer, and are in agreement with results from the five earlier
published prospective studies of circulating concentrations of
enterolactone in relation to risk for prostate cancer (Stattin et al,
2002, 2004; Kilkkinen et al, 2003; Low et al, 2006; Ward et al, 2008).
Our finding of a possible protective association of genistein with
prostate cancer risk is consistent with the experimental data from
in vivo and in vitro studies (Bingham et al, 1998; Bylund et al,
2000; Goetzel et al, 2007). This association may be mediated by
oestrogenic and/or a number of anti-carcinogenic properties,
although the biological effects of exposure to phyto-oestrogens in
humans remain uncertain (Bingham et al, 1998; Magee and
Rowland, 2004; McCann et al, 2005; McCormick et al, 2007).
Phyto-oestrogens have a structure similar to mammalian oestro-
gens and can bind to the oestrogen receptor (Morito et al, 2001;
Mueller et al, 2004). Experimental evidence suggests that the
interaction of isoflavones with the oestrogen receptor beta (ER-b)
might be particularly important in the development of prostate
cancer (Morito et al, 2001; McCarty, 2006); compared with
daidzein, genistein has a much greater affinity for the ER-b,
selectively promoting ER-b signalling which in turn may suppress
cellular proliferation and promote differentiation in the prostate
(McCarty, 2006; Ricke et al, 2007). It is unclear though whether the
levels of dietary phyto-oestrogen exposure in humans are
sufficiently high to exert a biological effect (Liggins et al, 2000b;
McCarty, 2006). The median circulating genistein concentration in
the top fifth of the distribution in this study, 14ngml
–1,i s
approximately seven times lower than the average concentration of
87ngml
–1for cases and 99ngml
–1for controls found in the study
of Japanese men (Ozasa et al, 2004). However, despite these lower
levels of phyto-oestrogens we found some evidence of an
association with prostate cancer risk.
We found no strong evidence for heterogeneity in the relation-
ship of plasma phyto-oestrogens with prostate cancer risk by age at
blood collection. These findings are consistent with an earlier
study, which found no significant associations after stratifying by
age (Stattin et al, 2004).
In this study, we were able to evaluate whether risk for prostate
cancer in relation to circulating phyto-oestrogen concentrations
varied by tumour characteristic. We found no evidence for a
difference in the relationship between plasma phyto-oestrogens
Table 4 Relative risk
a for prostate cancer by fifth of plasma phyto-oestrogen concentration
Fifth of phyto-oestrogen
1 (reference) 2345 P for trend
b
Isoflavones
Genistein
Range (ngml
–1) 0.05–0.30 0.40–1.40 1.50–2.80 2.90–6.90 7.00–567.70
Cases/controls 217/219 205/209 171/201 185/205 172/208
RR (95% CI) 1 (reference) 0.95 (0.72–1.26) 0.79 (0.59–1.06) 0.80 (0.59–1.08) 0.71 (0.53–0.96) 0.032
Adjusted RR (95% CI)
c 1 (reference) 1.00 (0.76–1.34) 0.81 (0.60–1.10) 0.80 (0.59–1.08) 0.74 (0.54–1.00) 0.051
Daidzein
Range (ngml
–1) 0.05–0.30 0.40–0.70 0.80–1.70 1.80–4.00 4.10–194.70
Cases/controls 237/245 140/178 212/215 173/199 188/205
RR (95% CI) 1 (reference) 0.79 (0.59–1.06) 0.93 (0.71–1.22) 0.79 (0.59–1.05) 0.82 (0.62–1.09) 0.368
Adjusted RR (95% CI)
c 1 (reference) 0.77 (0.57–1.05) 0.94 (0.71–1.24) 0.75 (0.56–1.02) 0.80 (0.60–1.07) 0.209
Equol
Range (ngml
–1)
d 0.05–0.05 0.10–0.20 0.30–0.40 0.50–0.70 0.80–41.30
Cases/controls 397/458 188/178 173/159 108/126 84/121
RR (95% CI) 1 (reference) 1.27 (0.98–1.63) 1.34 (1.03–1.76) 1.15 (0.84–1.58) 1.01 (0.72–1.41) 0.926
Adjusted RR (95% CI)
c 1 (reference) 1.24 (0.96–1.61) 1.34 (1.01–1.77) 1.11 (0.81–1.54) 0.99 (0.70–1.39) 0.461
Lignans
Enterolactone
Range (ngml
–1) 0.05–1.40 1.50–2.90 3.00–4.80 4.90–9.30 9.40–149.30
Cases/controls 202/209 196/212 153/207 223/208 176/206
RR (95% CI) 1 (reference) 0.97 (0.74–1.27) 0.76 (0.57–1.02) 1.12 (0.85–1.47) 0.88 (0.66–1.17) 0.673
Adjusted RR (95% CI)
c 1 (reference) 0.93 (0.71–1.23) 0.71 (0.53–0.96) 1.03 (0.78–1.36) 0.77 (0.57–1.04) 0.92
Enterodiol
Range (ngml
–1) 0.05–0.10 0.20–0.20 0.30–0.40 0.50–0.90 1.00–46.40
Cases/controls 329/349 114/127 150/183 172/183 185/200
RR (95% CI) 1 (reference) 0.97 (0.72–1.31) 0.88 (0.67–1.15) 0.97 (0.74–1.27) 0.93 (0.71–1.22) 0.774
Adjusted RR (95% CI)
c 1 (reference) 0.99 (0.72–1.34) 0.86 (0.65–1.14) 0.97 (0.73–1.27) 0.88 (0.67–1.16) 0.293
BMI¼body mass index; CI¼confidence interval; RR¼relative risk.
aCase patients and control participants were matched on recruitment centre, age at enrolment (±6 months),
time of day of blood collection (±1h), follow-up time (as close as possible), time between blood draw and last consumption of food or drinks (o3, 3–6, 46h).
bTest for trend
obtained by replacing the categorical variable with a continuous variable equal to the median concentration within each fifth of plasma phyto-oestrogen concentration.
cAdjustment was made for smoking (never, past and present), physical activity (inactive, moderately inactive and active), alcohol intake (o8, 8–15, 16–39, X40g per day),
marital status (married or cohabiting, not married or cohabiting), education (primary or none, secondary and degree level) and BMI (fourths).
dFor equol, given the high
proportion of values below the lower limit of detection and the interest in the comparison between non-producers and producers of equol, the grouping was as follows: not
detected (non-producers) and those with detectable levels of equol (producers) divided into four groups using the following cut-points, 0.30, 0.50 and 0.80ngml
–1.
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disease. These results are consistent with the findings from two
other studies, which also reported no association of circulating
enterolactone concentrations with localised or with advanced stage
disease (Stattin et al, 2002, 2004; Kilkkinen et al, 2003). To our
knowledge, no earlier published prospective studies have reported
results for prediagnostic concentrations of circulating isoflavones
in relation to prostate cancer risk stratified by tumour character-
istics. The conclusions that can be drawn from this study, however,
are limited by the small numbers in each category of tumour
characteristic, as shown by the width of the CIs.
The findings from this large prospective study in European men
suggest that higher concentrations of circulating genistein are
associated with a lower risk for prostate cancer. No evidence was
found for a protective association with plasma lignans. Further
large prospective analyses, and ultimately pooled analyses, are
needed to confirm this apparent association with genistein
concentration and to examine associations between the circulating
phyto-oestrogen concentrations and prostate cancer subtypes.
Given that the only established risk factors for the disease (age,
family history and ethnicity) are not amenable to modification, the
possible protective effect of genistein could offer an opportunity
for the development of a preventative intervention.
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